| Code | CSB-RA010053MB1HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is a research-grade biosimilar to indusatumab, designed to specifically target GUCY2C (Guanylate Cyclase 2C), a transmembrane receptor primarily expressed on intestinal epithelial cells. GUCY2C functions as a key regulator of intestinal fluid and electrolyte homeostasis through cyclic GMP signaling pathways. This receptor has gained significant attention in oncology research due to its overexpression in colorectal cancer and other gastrointestinal malignancies, while maintaining restricted expression in normal tissues, making it an attractive target for cancer therapeutics and diagnostics.
Indusatumab, the reference antibody, was developed as an investigational therapeutic agent for GUCY2C-positive tumors and has been explored in antibody-drug conjugate formats for targeted cancer therapy. This biosimilar antibody provides researchers with a valuable tool for investigating GUCY2C biology, studying receptor expression patterns in normal and malignant tissues, evaluating therapeutic targeting strategies, and exploring biomarker development in gastrointestinal cancers. It supports diverse research applications in cancer biology, immunotherapy development, and gastrointestinal physiology studies.
There are currently no reviews for this product.